

May 8, 2023
Fuji Pharma Co., Ltd.

Notice of Launch of "Nextstellis™" in Thailand and Commemorative Symposium

Fuji Pharma Co., Ltd. ("Fuji") announced that Fuji's Thai subsidiary, OLIC (Thailand) Limited ("OLIC") held a commemorative symposium titled "Take-off The 1st NE4ST with DRSP to the next era" ("the Symposium") on April 27 in Bangkok, on the occasion of the launch of "Nextstellis™".



This Symposium was organized by OLIC to commemorate the launch of Nextstellis™, a novel combination contraceptive containing estetrol and drospirenone, in Thailand. The title "NE4ST" is a word that is a cross between "NEST (Native Estrogen with Selective Actions in Tissues)" and "E4 (Estetrol)". More than 170 Thai obstetricians and gynecologists attended this symposium and reported clinical data on unmet medical needs in contraception and estetrol.

Nextstellis™ combines the native and selective estrogen, estetrol (E4) with drospirenone (DRSP). Estetrol has been confirmed to act selectively on estrogen receptors, and this selectivity is expected to provide a variety of benefits to patients. As announced in the October 24, 2022 press release titled "MITHRA AND FUJI ANNOUNCE APPROVAL OF NEXTSTELLIS™ IN THAILAND", the approval of import license has been obtained for the indication of contraception in Thailand. In Japan, the development name of it is FSN-013, and Fuji is currently making good progress in Phase III clinical trials for FSN-013 for the indication of "Dysmenorrhea" and "Improvement effect on pain associated with endometriosis"

With the launch of Nextstellis™ in Thailand, OLIC expands its business from a pure CMO company to a new hybrid company with CMO and pharmaceutical business with its own brand products. In addition, Fuji Pharma Group's first sales of pharmaceuticals in overseas markets have begun. We will continue to contribute to the well-being of women around the world by offering excellent pharmaceuticals.

For further information, contact

Fuji Pharma Co., Ltd.

Corporate Communication Section, Corporate Planning Department, Corporate Strategy Division

fsks@fujipharma.jp